150 related articles for article (PubMed ID: 3781341)
1. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin.
Stratton JA; Kucera PR; Rettenmaier MA; Dobashi K; Micha JP; Braly PS; Berman ML; DiSaia PJ
Gynecol Oncol; 1986 Nov; 25(3):302-10. PubMed ID: 3781341
[TBL] [Abstract][Full Text] [Related]
2. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
3. Concordance of combination and single agent chemosensitivity prediction in ovarian carcinoma using the subrenal capsule xenograft assay (SRCA).
Stratton JA; Rettenmaier MA; Kucera PR; Berman ML; DiSaia PJ
Gynecol Oncol; 1988 Jul; 30(3):416-21. PubMed ID: 3391423
[TBL] [Abstract][Full Text] [Related]
4. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
[TBL] [Abstract][Full Text] [Related]
5. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
Mäenpää J
Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
7. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
8. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
[TBL] [Abstract][Full Text] [Related]
9. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
[TBL] [Abstract][Full Text] [Related]
11. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
12. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia.
Lancet; 1987 Aug; 2(8555):353-9. PubMed ID: 2886821
[TBL] [Abstract][Full Text] [Related]
13. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer.
Hernádi Z; Juhász B; Póka R; Lampé LG
Int J Gynaecol Obstet; 1988 Oct; 27(2):199-204. PubMed ID: 2903085
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
[TBL] [Abstract][Full Text] [Related]
16. Treatment of stages II, III and IV primary surface epithelial ovarian cancers by maximum bulk tumour reduction and combined chemotherapy with cyclophosphamide, doxorubicin and cisplatin.
Khanna S; Kirwan P; Naftalin NJ; Aukett RJ
Clin Radiol; 1986 Mar; 37(2):187-91. PubMed ID: 3698507
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
Bertelsen K; Jakobsen A; Strøyer J; Nielsen K; Sandberg E; Andersen JE; Ahrons S; Nyland M; Hjortkjaer Pedersen P; Larsen G
Gynecol Oncol; 1993 Apr; 49(1):30-6. PubMed ID: 8482557
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
J Clin Oncol; 1991 Sep; 9(9):1668-74. PubMed ID: 1831495
[TBL] [Abstract][Full Text] [Related]
19. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide.
Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ
Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331
[TBL] [Abstract][Full Text] [Related]
20. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
Mäenpää JU; Heinonen E; Hinkka SM; Karnani P; Klemi PJ; Korpijaakko TA; Kuoppala TA; Laine AM; Lähde MA; Nuoranne EK
Gynecol Oncol; 1995 Jun; 57(3):294-8. PubMed ID: 7774832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
